Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET190L1-ARTEMIS in B-cell Leukemia and Lymphoma
NCT03895944Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of ET019003 in B cell lymphoma and B-cell leukemia (BCL) (3 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Frequency of ARTEMIS T cell treatment-related adverse events at 24 weeks, Number of ET190L1-ARTEMIS™ T cells in peripheral blood at 24 months and 2 more. Status: unknown.
02
Drugs
ET019003
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT03895944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895944.